Advanced Cholangiocarcinoma Clinical Trial
Official title:
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
Adult patients with histologically or cytologically confirmed advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or translocations or other FGFR genetic alterations have been enrolled. Subjects must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/metastatic disease. Subjects should have had evidence of progressive disease following their prior regimen or if prior treatment was discontinued due to toxicity must have continued evidence of measurable disease. Up to approximately 160 adult patients over age 18, both male and female were planned for enrollment. Three cohorts of subjects comprise the study population: Cohort 1: subjects with FGFR2 gene fusions (ie, fusions or rearrangements [formerly translocations]). Cohort 2: subjects with FGFR genetic alterations other than FGFR2 gene fusions or rearrangements. Cohort 3: subjects with FGFR2 gene fusions or rearrangements who have received a prior FGFR inhibitor. All subjects received oral BGJ398 (infigratinib), once-daily, on a three weeks on (21 days), one week off (7 days) schedule. One treatment cycle consists of 28 days. Notes: Cohort 1 was pre-specified as the primary analysis population. Results of these analyses were previously disclosed (posted 22 June 2022). There were no additional efficacy or safety endpoints to assess in Cohort 1 after primary completion (01 March 2021). Cohorts 2 and 3 were added at protocol amendment (PA) 4 to support only exploratory efficacy objectives of the study. These cohorts were ongoing the time of primary completion (01 March 2021). After interim review of the data from these cohorts (as permitted by the protocol) only limited efficacy was observed and the sponsor terminated the study early. Therefore, a formal efficacy analysis was not performed for Cohorts 2 and 3. However, baseline characteristics and safety data were analyzed. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05823311 -
Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
|
Phase 3 | |
Not yet recruiting |
NCT06439485 -
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
|
Phase 2 | |
Recruiting |
NCT06420349 -
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
|
Phase 1 | |
Recruiting |
NCT05727176 -
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
|
Phase 2 | |
Recruiting |
NCT05791448 -
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
|
Phase 1 | |
Active, not recruiting |
NCT04093362 -
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|
Phase 3 | |
Recruiting |
NCT03996408 -
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02982720 -
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
|
Phase 2 | |
Recruiting |
NCT03982680 -
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT05532059 -
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
Terminated |
NCT04088188 -
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
|
Phase 1 | |
Completed |
NCT02989857 -
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
|
Phase 3 | |
Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
Terminated |
NCT03773302 -
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
|
Phase 3 | |
Approved for marketing |
NCT04507503 -
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|